[HTML][HTML] Initial genome sequencing and analysis of multiple myeloma
Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly
understood. Here we report the massively parallel sequencing of 38 tumour genomes and …
understood. Here we report the massively parallel sequencing of 38 tumour genomes and …
Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and …
S Trudel, N Lendvai, R Popat, PM Voorhees… - The Lancet …, 2018 - thelancet.com
Background B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis
superfamily required for plasma cell survival. BMCA is universally detected on patient-…
superfamily required for plasma cell survival. BMCA is universally detected on patient-…
[PDF][PDF] Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
…, YA Efebera, S Jagannath, A Chari, S Trudel… - Cancer cell, 2014 - cell.com
We performed massively parallel sequencing of paired tumor/normal samples from 203
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
…, AJ Jakubowiak, S Lonial, S Trudel… - Blood, The Journal …, 2012 - ashpublications.org
Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the
treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 …
treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 …
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Background Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell
maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily …
maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily …
[HTML][HTML] Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma
PG Richardson, S Trudel, R Popat… - … England Journal of …, 2023 - Mass Medical Soc
Background Despite recent progress, multiple myeloma remains incurable. Mezigdomide is
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
CB Reeder, DE Reece, V Kukreti, C Chen, S Trudel… - Leukemia, 2009 - nature.com
We have studied a three-drug combination with cyclophosphamide, bortezomib and
dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple myeloma (…
dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple myeloma (…
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4; 14) multiple myeloma
S Trudel, ZH Li, E Wei, M Wiesmann, H Chang, C Chen… - Blood, 2005 - ashpublications.org
The t(4;14) translocation that occurs uniquely in a subset (15%) of patients with multiple
myeloma (MM) results in the ectopic expression of the receptor tyrosine kinase (RTK), fibroblast …
myeloma (MM) results in the ectopic expression of the receptor tyrosine kinase (RTK), fibroblast …
TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding
…, R Figueredo, M Pampillo, J Koropatnick, S Trudel… - Clinical cancer …, 2017 - AACR
Purpose: The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic
(do not eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. …
(do not eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. …
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal …
Background On the basis of the DREAMM‐2 study (ClinicalTrials.gov identifier NCT03525678),
single‐agent belantamab mafodotin (belamaf) was approved for patients with relapsed …
single‐agent belantamab mafodotin (belamaf) was approved for patients with relapsed …